{"schema_version":"secwatch.filing_event.v1","accession":"0001639691-25-000008","form_type":"8-K","ticker":"LIVN","cik":"0001639691","company_name":"LivaNova PLC","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.271423+00:00","generated_at":"2026-05-26T04:47:41.076687+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LivaNova Q4 revenue $321.8M (+6.8% organic); FY2025 adjusted EPS guidance $3.65-$3.75","bullets":["Q4 revenue $321.8M (+6.8% organic YoY); GAAP EPS $1.02, adjusted EPS $0.81.","FY2024 revenue $1.25B (+10.7% organic); GAAP EPS $1.16, adjusted EPS $3.38.","FY2025 guidance: constant-currency revenue growth 5-6%, adjusted EPS $3.65-$3.75, adjusted FCF $135-155M.","OSPREY sleep apnea study met primary safety and efficacy endpoints at 6 months; RECOVER depression study publications support VNS Therapy.","Natalia Kozmina appointed Chief Human Resources Officer in January 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001639691-25-000008","json":"https://secwatch.observer/filing/0001639691-25-000008.json","markdown":"https://secwatch.observer/filing/0001639691-25-000008.md","text":"https://secwatch.observer/filing/0001639691-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1639691/000163969125000008/0001639691-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1639691/000163969125000008/livn-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:47:41.076687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}